Dublin, Ireland – November 17, 2021: Cosmo Pharmaceuticals NV (SIX: COPN, XETRA: C43) (‘Cosmo’) today announced that GI Genius(TM) has received regulatory approval in Canada.

GI Genius(TM) is an AI-powered endoscopy tool for the detection of colorectal lesions during colonoscopy. The GI Genius(TM) Intelligent Endoscopy Module provides a transformative solution based on Artificial Intelligence (AI) to address the challenges of early detection of colon cancer.

GI Genius(TM) was developed by Cosmo and is sold worldwide by Medtronic, the world leader in medical technology. GI Genius(TM) is already approved in the US, EU, Israel, UAE and Australia.

GI Genius(TM) works in real time as a tool for gastroenterologists to uncover areas of visual features during a colonoscopy that correspond to a variety of mucosal abnormalities, eg. B. Colorectal polyps of all shapes, sizes and morphologies. It has been designed so that it can be integrated into all existing gastrointestinal endoscopes.

Cosmo CEO Alessandro Della Cho commented: ‘It is heartening to see that GI Genius(TM) is fast becoming a true global franchisee.’

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and marketing products for the treatment of selected gastrointestinal diseases and improving quality measures in endoscopy by aiding in the detection of intestinal lesions. Cosmo has also developed medical equipment for endoscopy and has partnered with Medtronic to worldwide sell GI Genius(TM), an artificial intelligence device that helps detect signs of colon cancer. Cosmo has sold Amcolo(R) to Red Hill Biopharma Ltd. for the United States and Relfolk (R) by Dr. Falk GmbH is licensed to the European Union and other countries. For more information about Cosmo and its products, please visit the company’s website: www.cosmopharma.com